2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate

We are 2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate CAS:122111-11-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:
2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate
CAS.NO:122111-11-9
Synonyms:((2R,3R)-3-(Benzoyloxy)-4,4-difluoro-5-((methylsulfonyl)oxy)tetrahydrofuran-2-yl)methyl benzoate
2-Deoxy-2,2-difluoro-D-erythro-ribofuranose-3,5-dibenzoate 1-Methanesulfonate
Molecular Formula:C20H18F2O8S
Molecular Weight:456.41400
 
Physical and Chemical Properties:
Density:1.84
Melting point:66-74ºC
Boiling point:482.7ºC
Flash point:245.7ºC
Index of Refraction:1.652
 
Specification:
Appearance:Off-white to pale yellow solid
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Gemcitabine intermediate

2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate


Related News: The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.2 – ((2-nitro-4- (trifluorometil) fenil) amino) etanol CAS:10442-83-8 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.Bis(2,6-difluoro-3-(1-hydropyrrol-1-yl)phenyl)titanocene CAS:125051-32-3 The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.1,4'-bipiperidine CAS:4897-50-1 In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.

Related Products
Product Name
Pralmorelin View Details
Ethyl 4-dimethylaminobenzoate View Details
Tetramethyldisiloxane View Details
N,N-dimethyl-1,4-phenylenediamine manufacturer 2-fluoroadenosine manufacturer (1-benzoyl-2-oxo-4-phenylazetidin-3-yl) acetate manufacturer Methyl pivaloylacetate manufacturer Cyclopropyl-2-fluoro benzyl ketone manufacturer